Trevi Therapeutics, Inc.

For the period ended Jun 30, 2025. Filed Aug 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 7, 2025

TRVI$14.91-2.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Comprehensive Loss

(Amounts in thousands, except share and per share amounts)

	Three Months EndedJune 30,		Six Months EndedJune 30,
	2025	2024	2025	2024
Operating expenses:
Research and development	$9,389	$10,021	$17,200	$18,825
General and administrative	4,333	3,268	7,992	6,370
Total operating expenses	13,722	13,289	25,192	25,195
Loss from operations	(13,722)	(13,289)	(25,192)	(25,195)
Other income (expense):
Interest income, net	1,407	935	2,532	1,933
Other expense, net	(7)	(5)	(13)	(6)
Interest expense	—	(1)	—	(2)
Total other income, net	1,400	929	2,519	1,925
Loss before income taxes	(12,322)	(12,360)	(22,673)	(23,270)
Income tax benefit	21	8	32	16
Net loss	$(12,301)	$(12,352)	$(22,641)	$(23,254)
Basic and diluted net loss per common share outstanding	$(0.09)	$(0.12)	$(0.18)	$(0.23)
Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted	130,350,391	101,041,573	124,015,763	100,279,393
Net loss	$(12,301)	$(12,352)	$(22,641)	$(23,254)
Other comprehensive loss:
Net unrealized losses on available-for-sale marketable securities	(49)	(17)	(37)	(55)
Comprehensive loss	$(12,350)	$(12,369)	$(22,678)	$(23,309)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.